scholarly article | Q13442814 |
P356 | DOI | 10.1002/CMDC.200700181 |
P698 | PubMed publication ID | 18338369 |
P50 | author | Supa Hannongbua | Q42871449 |
P2093 | author name string | Pensri Srivab | |
P2860 | cites work | Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase | Q27628304 |
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance | Q27631898 | ||
Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors | Q27635069 | ||
Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant | Q27638329 | ||
High resolution structures of HIV-1 RT from four RT-inhibitor complexes | Q27729427 | ||
Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance | Q27766013 | ||
Theoretical studies of enzymic reactions: dielectric, electrostatic and steric stabilization of the carbonium ion in the reaction of lysozyme | Q28291671 | ||
L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase | Q28378789 | ||
The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors | Q29039690 | ||
Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. | Q30342229 | ||
Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection | Q33631716 | ||
Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase | Q34047516 | ||
Antiviral drugs in current clinical use. | Q34547577 | ||
Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. | Q34575882 | ||
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives | Q34595452 | ||
Modeling biotransformation reactions by combined quantum mechanical/molecular mechanical approaches: from structure to activity | Q35137594 | ||
New challenges in quantum chemistry: Quests for accurate calculations for large molecular systems | Q35153408 | ||
Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs | Q35796056 | ||
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). | Q36072382 | ||
Modelling enzyme reaction mechanisms, specificity and catalysis. | Q36299121 | ||
HIV reverse transcriptase structure-function relationships | Q36657162 | ||
The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations | Q39268433 | ||
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. | Q40425001 | ||
Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase | Q41346135 | ||
Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. | Q43678172 | ||
Conformational analysis of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, based on quantum mechanical calculations | Q43979142 | ||
Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase | Q44570491 | ||
Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues | Q44844445 | ||
Quantum study of mutational effect in binding of efavirenz to HIV-1 RT. | Q46403165 | ||
Molecular mechanics PBSA ligand binding energy and interaction of Efavirenz derivatives with HIV-1 reverse transcriptase | Q46558469 | ||
Performance Evaluation of the Three-Layer ONIOM Method: Case Study for a Zwitterionic Peptide. | Q51629310 | ||
Combining Quantum Mechanics Methods with Molecular Mechanics Methods in ONIOM. | Q51630551 | ||
Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V | Q57480046 | ||
Conformational study of the HIV-1 reverse transcriptase inhibitor 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) | Q77296519 | ||
Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives | Q80141775 | ||
Binding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl TIBO complex structures: quantum chemical calculations based on the ONIOM method | Q81394699 | ||
P433 | issue | 5 | |
P921 | main subject | efavirenz | Q422645 |
P304 | page(s) | 803-811 | |
P577 | publication date | 2008-05-01 | |
P1433 | published in | ChemMedChem | Q2962252 |
P1476 | title | A study of the binding energies of efavirenz to wild-type and K103N/Y181C HIV-1 reverse transcriptase based on the ONIOM method | |
P478 | volume | 3 |
Q48578132 | A toolkit to assist ONIOM calculations. |
Q46230871 | Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine |
Q44285867 | Key role of hydrazine to the interaction between oxaloacetic against phosphoenolpyruvic carboxykinase (PEPCK): ONIOM calculations |
Q54549089 | Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT. |